App-Quantinova.ai

Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma

Maria Roussou - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Dexamethasone

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Andrzej Jakubowiak - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Dexamethasone

Gas6-Induced Tissue Factor Expression in Endothelial Cells Is Mediated Through Caveolin-1-Enriched Domains

Catherine A Lemarie - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

L-Tyrosine

Genetic Determinants of Plasma Von Willebrand Factor (VWF) and VWF Propeptide Levels

Ayse Bilge Ozel - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Incidence of Heparin Induced Thrombocytopenia in the Transplant Population: A Large Retrospective Cohort, Single Transplant Centre Experience

Dania Khoulani - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Evithrom

TLR3 Activation Is Involved in Venous Thrombosis Development

Angela Le - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Incidence of Direct Thrombin Inhibitor Therapy for Presumed Heparin Induced Thrombocytopenia Before and After Implementation of Heparin Induced Thrombocytopenia IgG Subtype Antibody Test

John L. Reagan - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Argatroban

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice Interim Results From a Large, European, Observational Study

Dominik Selleslag - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Romiplostim

Changes of ADAMTS13 Activity and VWF Level in the Plasma of Patients Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)

Luping Hu - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Heparin-Induced Thrombocytopenia and Thrombosis: Therapeutic Strategy Using a Single-Chain Variable Fragment (scFv) Antibody

Jose Perdomo - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

In Vitro and in Vivo Neutralization of Murine Activated Protein C

Jose A. Fernandez - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Protein C

Factor V Inhibits PAR2-Mediated Lethal Inflammation

Hai-Po Helena Liang - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Protein C

FXII Promotes Coagulation in a FXI and FIX Independent Manner

Zoe C Wong - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

An RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates

Alfica Sehgal - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

FVIII

A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant

Luke Law - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Adrenaclick

Frequency and Determinants of Thrombotic and Bleeding Complications in Ph Negative Myeloproliferative Neoplasms (MPN): The Role of Adamts-13 and VWF Activities in an Italian Cohort 0f 88 Well Characterized Patients

Maria C Carraro - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Methadone hydrochloride

An Elevated TRV Is Associated with Venous Thromboembolism in Sickle Cell Disease

Lianne S Kopel - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

CH50 Activity Correlates with Residual Intravascular Hemolysis in Pts with Paroxysmal Nocturnal Hemoglobinuria Treated by Eculizumab

Veronique Fremeaux-Bacchi - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Eculizumab

Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.

Margaret V. Ragni - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Hospital-Acquired DVT/PE As Never Events: A Misguided Strategy for Performance Improvement in VTE Prevention.

Brandyn Daniel Lau - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Venous thrombosis

N/A

Filters

7277 Abstracts